Feature

Cancer patients report delays in treatment because of COVID-19


 

Taking action

“ACS CAN is working every day to make clear to Congress and the administration the real and immediate challenges cancer patients and survivors face during this pandemic,” said Brooks-Coley.

With nearly 50 other professional and advocacy groups, ACS CAN has sent letters to congressional leadership and the Secretary of the Department of Health & Human Services asking them to make policy changes that would help patients.

The proposed action points include having insurers allow patients to use providers who are out of network if necessary; waiving site-specific precertification and prior authorization for cancer treatment; utilizing shared decision making between patients and providers in deciding whether to use home infusion without pressure from the insurer; allowing patients to obtain 90-day supplies of medication; increasing funding for state Medicaid programs and assistance for those who have lost employee-sponsored coverage; and improving telehealth services.

“We urge Congress and the administration to keep the needs of cancer patients and survivors in mind as they continue to address the public health crisis,” she said.

This article first appeared on Medscape.com.

Pages

Recommended Reading

No hydroxychloroquine benefit in small, randomized COVID-19 trial
MDedge Hematology and Oncology
Sleep in the time of COVID-19
MDedge Hematology and Oncology
Evidence suggests possible RAS-blocker benefit in COVID-19 patients
MDedge Hematology and Oncology
Imaging recommendations issued for COVID-19 patients
MDedge Hematology and Oncology
COVID-19 pandemic spells trouble for children’s health
MDedge Hematology and Oncology
Cancer care ‘transformed in space of a month’ because of pandemic
MDedge Hematology and Oncology
COVID-19: Press pause on assisted reproduction?
MDedge Hematology and Oncology
Hospitalist well-being during the COVID-19 crisis
MDedge Hematology and Oncology
Protean manifestations of COVID-19: “Our ignorance is profound”
MDedge Hematology and Oncology
Can convalescent plasma treat COVID-19 patients?
MDedge Hematology and Oncology